---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-017052"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T14:43:40.617081+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biofrontera acquires US Ameluz/RhodoLED rights, cuts royalty to 12%, gets $11M financing

## Summary
- Acquires all US assets for Ameluz and RhodoLED including NDA and patents from Biofrontera AG.
- Effective royalty rate reduced from 25-35% of net sales to 12% (15% above $65M revenue).
- Receives $11M investment led by Rosalind Advisors and AIGH Capital Management, funding to profitability.
- Biofrontera AG to receive 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.
- First tranche of $8.5M funded at signing; second tranche of $2.5M due upon final asset transfer agreement by Sep 30, 2025.

## SEC filing metadata
- accession: 0001641172-25-017052
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000164117225017052/0001641172-25-017052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000164117225017052/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-017052
- JSON: https://secwatch.observer/filing/0001641172-25-017052.json
- Plain text: https://secwatch.observer/filing/0001641172-25-017052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.